Skip to content

Understanding mechanisms of prevention of depression: a mechanistic cross-over trial of mindfulness vs. fantasizing to reduce perseverative cognition underlying vulnerability for depression

Understanding mechanisms of prevention of depression: a mechanistic cross-over trial of mindfulness vs. fantasizing to reduce perseverative cognition underlying vulnerability for depression - MINDCOG

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON52825
Enrollment
100
Registered
2019-10-09
Start date
2020-06-19
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression, Major Depressive Disorder depression

Interventions

All participants will receive two interventions, a mindfulness intervention and a positive fantasizing intervention. For both interventions, participants will first receive a professional training f

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: All participants will be between 18 and 60 years of age. Participating patients will have experienced at least two major depressive episodes (experienced in the past ten years) and are in (partial or complete) remission from a depressive episode (for more than 2 months).

Exclusion criteria

Exclusion criteria: Participants should not have any current DSM-5 diagnoses, should currently not use anti-depressant medication (i.e. >4 weeks) have not received protocolized preventive cognitive therapy for their last episode or have recent (daily practice) experiences with mindfulness. Healthy participants should furthermore show no life-time psychopathology.

Design outcomes

Primary

MeasureTime frame
The main study parameters of study 1 and 2 concern: i) indices of PC, namely daily fluctuations in self-reported PC (using ESM), reported PC during an experimental task (using SART), physiological correlates of PC (using HR/HRV) and electrophysiological correlates of PC (using EEG). The endpoint of study 1 is within-subject (fantasizing vs. mindfulness) differences in the extent to which PC changes pre- and peri-intervention performance of the interventions as measured with the main study parameters. The endpoint of study 2 is between-group (remitted MDD vs. HC) differences in the extent to which PC changes pre- and peri-intervention performance of the interventions as measured with the main study parameters. The main study parameters of study 3 concern measures of potential individual treatment markers (e.g. PC characteristics, physiological characteristics, personality). The endpoint of study 3 is the correlation between pre-intervention individual characteristics and the efficacy of mindfulness and fantasizing.

Secondary

MeasureTime frame
Secondary parameters of study 1 concern: i) measures of depressive symptoms and other factors that are potent in being influenced by the interventions (measures with self-report questionnaires: IDS-SR [depressive symptomology], FFMQ [mindfulness], PANAS [positive and negative affect states], LARSS [ruminative thinking on sadness], ERQ [emotion regulation strategies], RPA-NL [ruminative thought in response to positive affect], PTQ [perseverative thinking]) and ii) actigraphy measures reflecting sleep patterns and iii) indices of PC as measured with self-report questions (during SART tasks and ESM), EEG and ICG/ECG (during the SART and emotion regulation).

Countries

Netherlands

Contacts

Public ContactM.J. van Tol

Universitair Medisch Centrum Groningen

m.j.van.tol@umcg.nl+31503616405

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Apr 17, 2026